INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.
|Published (Last):||10 June 2010|
|PDF File Size:||12.44 Mb|
|ePub File Size:||16.45 Mb|
|Price:||Free* [*Free Regsitration Required]|
Iron dextran injection contains 50 mg of elemental iron prescrbing mL. The first stage involves an inflammatory reaction at the site of injection which aids the passage of the drug into the lymphatic system.
U.S. Prescribing Information Disclaimer
The type of anemia and the underlying cause or causes should be determined before starting therapy with parenteral iron dextran. There are limits to the volume of iron dextran that may be injected IM per 24 hours based on patient age and weight; see dosage guidelines. Parenteral iron supplement of ferric oxyhydroxide complexed with dextrans; rapidly repletes iron stores in deficiency from anemia or blood loss; sometimes associated with severe hypersensitivity.
Slow intermittent intravenous IV injection: However, trace amounts of unmetabolized iron dextran are excreted in breast milk. There are no adequate and well-controlled studies in pregnant women. Your Name Your name is required. If test dose uneventful, give the remainder of the total dose as mg of elemental iron per day IM or slow IV until the total calculated dose is given.
If test dose uneventful, give the remainder of the total dose as 25 mg of iron dextran per day IM or slow IV until the total calculated dose see equation is given.
Iron dextran (INFeD) | – A Hematology Oncology Wiki
INFeD is administered by intramuscular or intravenous injection. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. Do not innfed iron during dimercaprol treatment.
If test dose uneventful, infuse the remainder of the total calculated dose IV over 2 to 6 hours. Major Deferiprone chelates iron.
Serum iron, hemoglobin and hematocrit should be evaluated prior to iron therapy and at regular intervals during therapy. To avoid staining of subcutaneous tissue, use the Z-track technique of injection. Iinformation taken into reticuloendothelial cells, the iron from the iron dextran niformation is separated and added to the body’s total iron stores.
Transferrin delivers iron to specific receptors for deposit, where it is either incorporated into hemoglobin or oxidized and stored in combination with apoferritin as ferritin. Major Parenteral iron formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory. Most patients with chronic kidney disease will require supplemental iron e.
Iron dextran is classified in FDA pregnancy risk category C.
Once the infusion is completed, flush vein with NS injection. It would be illogical for a patient to receive both iron supplementation and deferasirox simultaneously. Consult specialized references for amount of test dose to be given. Parenteral iron dextran therapy is associated with a risk of serious hypersensitivity reactions or anaphylaxis.
If the patient is standing, inject iron dextran into the buttock opposite the weight-bearing leg. Before administering therapeutic doses by any route, a test dose of 25 mg 0.
Give DexFerrum test doses gradually over at least 5 minutes. Facilities for cardiopulmonary resuscitation and personnel trained in the detection and treatment of anaphylactoid reactions must be available during administration. Infants and Children 4 months and older weighing 5 to 9.
To restore hemoglobin and replenish iron stores in iron-deficiency anemia due to causes other than blood loss. Hemosiderosis secondary to long-term iron dextran treatment has primarily been reported in patients with renal failure receiving dialysis. Cardiac disease, hypotension, intravenous administration.